Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 9, 2003, Pages 1972-1976

  Amirkhosravi, A ^a   Mousa, S A ^a,b   Amaya, M ^a   Francis, J L ^a  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Low molecular weight heparin; Metastasis; Thrombosis; Tissue factor pathway inhibitor

Indexed keywords

FIBRINOLYTIC AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL; ARTICLE; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL MELANOMA; HUMAN; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIPOPROTEINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; PLATELET COUNT; THROMBOCYTOPENIA; UMBILICAL VEINS;

EID: 1842463681     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00341.x     Document Type: Article

References (44)

1. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-4-8.
2. Bick RL. Coagulation abnormalities in malignancy-a review. Semiti Thromb Hemost 1992; 18: 353-72.
3. Sun NCJ, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part 1. Coagulation studies. Am J Clin Pathol 1979; 71: 10-6.
4. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989; 42: 805-9.
5. Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med 1996; 239: 153-6.
6. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
7. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc NatlAcad Sci USA 1992; 89: 11832-6.
8. Amirkhosravi M, Francis JL. Coagulation activation by MC28 fibro sarcoma cells facilitates lung tumor formation. Thromb Haemost 1995; 73: 59-65.
9. Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease. Am J Physiol 1997; 273: H2091-H2104.
10. Mousa SA. Mechanisms of angiogenesis in vascular disorders. Potential therapeutic targets. In: Mousa S, ed. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Georgtown, TX: R.G. Landes, 2000; I: 1-12.
11. Nemerson Y Tissue factor: then and now. Thromb Haemost 1995; 74: 180-4.
12. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experi mental tumor dissemination. Semin Thromb Hemost 2002; 28: 29-38.
13. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Nati Acad Sci USA 1995; 92: 8205-9.
14. Kudrijashov BA, Kalishevskaya TM, Kolomina SM. Blood anticoagu-lating system and malignant tumors. Nature 1969; 222: 548-50.
15. Fisher B. Experimental studies of factors which influence hepatic metastases. VII. Effects of anticoagulants. Surg 1961; 50: 240-7.
16. Agostino D, Cliffton EE. Anticoagulants and the development of pulmonary metastases. Arch Surg 1962; 84: 449-53.
17. Owen CA Jr. Anticoagulant treatment of rats with Walker 256 carci-nosarcomas. J Cancer Res Clin Oncol 1982; 104: 191-3.
18. Drago JR, Weed P, Fralisch A. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma. Anticancer Res 1984; 4: 171-2.
19. Saba TM, Cho E. Alteration of tumor growth by a purified alpha-2-glycoprotein. J Reticuloendothelial Soc 1977; 22: 583-96.
20. Sylvester DM, Liu YS, Meadows GG. Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin. Immuno-pharmacol Immunotoxicol 1990; 12: 161-80.
21. Amirkhosravi M, Francis JL. Procoagulant activity of the MC28 fibrosar coma cell line in vitro and in vivo. Br J Haematol 1993; 85: 736-44.
22. Wong NN. Drug Highlight tinzaparin. Heart Dis 2002; 4: 331-40.
23. Fegan CD. Drug focus. Tinzaparin as an antithrombotic: an overview. Hospital Med 1998; 59: 145.
24. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002; 26: 45-51.
25. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 930-6.
26. Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and sub cutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-85.
27. Tsakiris D, Scudder L, Hodivala-Dilke K, Hynes OR, Coller BS. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 1999; 81: 177-88.
28. Goldberg RJ, Seneff M, Gore JM. Occult malignant neoplasm in patients with deep venous thrombosis. Ann Intern Med 1987; 147: 251-3.
29. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1998; 318: 404-7.
30. Rickles FR, Edwards RL. Activation of blood coagulation in cancer; Trousseau's syndrome revisited. Blood 1982; 62: 14-31.
31. Kakkar AJ, Williamson RC. Prevention of venous thromboembolism in cancer using low molecular weight heparin. Haemostasis 1997; 27 (Suppl. 1): 32-7.
32. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, Gordon SG, Barbui T Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92: 143-51.
33. Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemo stasis 2001; 31 (Suppl. 1): 11-5.
34. Amirkhosravi A, Jiao J, Amaya M, Meyer T, Francis JL, Wong H. The suppression of tumor cell procoagulant activity, experimental metastasis and primary tumor growth by monoclonal antibodies against tissue factor. Thromb Haemost 2001; (Suppl.): OC1021.
35. Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha lib beta 3 expression on the cell surface. Thromb Res 1992; 68: 233-45.
36. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin lib-Ilia, fibronectin and von Willebrand factor on tumor adhe sion in vitro and metastasis in vivo. Thromb Haemost 1995; 74: 282-90.
37. Dardik R, Savion N, Kaufmann Y, Varon D. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions. Role of platelet glycoproteins P-selectin and GPIIb-Illa. Br J Cancer 1998; 77: 2069-75.
38. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991; 87: 229-36.
39. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992; 11: 325-35.
40. Walz DA, Fenton JW. The role of thrombin in tumor cell metastasis. Invasion Metastasis 1994; 14: 303-8.
41. Lee AE, Rogers LA, Jeffery RE, Longcroft JM. Comparison of meta static cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis 1988; 6: 463-71.
42. Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824-9.
43. Mousa SA, Bozarth JW, Hainer P, Sprogel K, Barrett JS. Pharmaco-dynamic effects of tinzaparin following 175 IU/Kg subcutaneous administration in healthy volunteers on plasma tissue factor pathway inhibitor (TFPI). Thromb Haemost 2001; (Suppl.): P2299.
44. Mousa SA, Mohamed S. Anti-angiogenic efficacy & mechanism of the low molecular weight heparin (LMWH), tinzaparin and tissue factor pathway inhibitor (TFPI): potential anticancer benefits. Thromb Haemost 2001; (Suppl): P1981